Adriana Mello Rodrigues
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adriana Mello Rodrigues has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Rita de Cássia Barbosa da Silva Tavares
Instituto Nacional do Câncer – Rio de Janeiro (RJ), Brazil
3 shared publications - Adriana Koliski
Pediatric Intensive Care Unit, Complexo Hospital de Clínicas da Universidade Federal do Paraná, Brazil
2 shared publications - Carla Nolasco Monteiro Breviglieri
Hospital Samaritano de São Paulo – São Paulo (SP), Brazil
2 shared publications - Carmem Bonfim
Duke University – Durham – Carolina do Norte – Estados Unidos
2 shared publications Gisele Loth
Instituto de Pesquisa Pelé Pequeno Príncipe/Hospital Pequeno Príncipe, Curitiba, Brazil
2 shared publications- Liane Esteves Daudt
Universidade Federal do Rio Grande do Sul, Bone Marrow Transplant Department, Porto Alegre, Brazil
2 shared publications
Latest Publications
- 24 July 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1344-1350
Outcomes of hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia: a multicenter Brazilian cohort study
Acute leukemias are prevalent among children and adolescents, with survival rates exceeding 90%, but high-risk cases often require hematopoietic stem cell transplantation (HSCT). Limited data are available on HSCT outcomes for pediatric acute lymphoblastic leukemia (ALL) in low- and middle-income countries. This Brazilian multicenter retrospective cohort study analyzed outcomes of ALL patients aged up to 18 years who underwent HSCT from January 2010 to June 2020. A total of 439 patients were included (69% male, 78.9% B-ALL). Unrelated donor transplants accounted for 49.9%, and haploidentical transplants for 18.9%. Bone marrow (82.6%) was the predominant stem cell source. Transplants occurred in the first or second complete remission (CR) in 38.7% and 44.2% of cases, respectively. The 100-day cumulative incidence of acute GvHD was 46.1%, and chronic GvHD after 100 days occurred in 25.5%. At five years, overall survival and event-free survival were 52.4% and 51.7%. By day +100, sepsis was the leading cause of mortality (42.3%), whereas relapse accounted for 76.3% of deaths thereafter. Findings align with HSCT literature, demonstrating similar outcomes despite challenges in developing countries and providing a basis for further research.
- 24 July 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1344-1350
Outcomes of hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia: a multicenter Brazilian cohort study
Acute leukemias are prevalent among children and adolescents, with survival rates exceeding 90%, but high-risk cases often require hematopoietic stem cell transplantation (HSCT). Limited data are available on HSCT outcomes for pediatric acute lymphoblastic leukemia (ALL) in low- and middle-income countries. This Brazilian multicenter retrospective cohort study analyzed outcomes of ALL patients aged up to 18 years who underwent HSCT from January 2010 to June 2020. A total of 439 patients were included (69% male, 78.9% B-ALL). Unrelated donor transplants accounted for 49.9%, and haploidentical transplants for 18.9%. Bone marrow (82.6%) was the predominant stem cell source. Transplants occurred in the first or second complete remission (CR) in 38.7% and 44.2% of cases, respectively. The 100-day cumulative incidence of acute GvHD was 46.1%, and chronic GvHD after 100 days occurred in 25.5%. At five years, overall survival and event-free survival were 52.4% and 51.7%. By day +100, sepsis was the leading cause of mortality (42.3%), whereas relapse accounted for 76.3% of deaths thereafter. Findings align with HSCT literature, demonstrating similar outcomes despite challenges in developing countries and providing a basis for further research.
- 26 January 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (4) , 474-481
Hematopoietic stem cell transplantation in inborn errors of metabolism—a retrospective analysis on behalf of the pediatric disease working party from the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy
Hematopoietic stem cell transplantation (HSCT) is an established treatment for selected patients with inborn errors of metabolism. In this first report from the PDWP-SBTMO, we included 105 patients transplanted between 1988 and 2021 across six Brazilian HSCT centers. The most prevalent diseases were X-linked adrenoleukodystrophy (n = 61) and mucopolysaccharidosis (type I n = 20; type II n = 10), with a median age at HSCT of 8.7 years and 2.1 years, respectively. Most conditioning regimens were myeloablative and busulfan-based. With a median follow-up of 6.7 years, the 5-years overall survival (OS) was 75% (95% CI, 0.65–0.82) with a superior 5-years OS for those transplanted after 2010 (87% vs. 63%, p = 0.01). Higher risk of death was associated with the use of haploidentical donor (HR8.86, p 0.021), unrelated cord blood (HR 8.76, p 0.005), unrelated donor (HR 5.91, p 0.02), and for HSCT performed before 2010 (HR 4.16, p = 0.0015). The CI of acute GVHD was 24.8%, while chronic GVHD was 9.5%. Major causes of death were infections (n = 8), GVHD (n = 6), and neurologic progression (n = 3). Despite improvements in transplant outcomes since 2011, challenges persist, emphasizing the need for early diagnosis, timely transplantation and expanding HSCT centers with expertise in the field.
- 26 January 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (4) , 474-481
Hematopoietic stem cell transplantation in inborn errors of metabolism—a retrospective analysis on behalf of the pediatric disease working party from the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy
Hematopoietic stem cell transplantation (HSCT) is an established treatment for selected patients with inborn errors of metabolism. In this first report from the PDWP-SBTMO, we included 105 patients transplanted between 1988 and 2021 across six Brazilian HSCT centers. The most prevalent diseases were X-linked adrenoleukodystrophy (n = 61) and mucopolysaccharidosis (type I n = 20; type II n = 10), with a median age at HSCT of 8.7 years and 2.1 years, respectively. Most conditioning regimens were myeloablative and busulfan-based. With a median follow-up of 6.7 years, the 5-years overall survival (OS) was 75% (95% CI, 0.65–0.82) with a superior 5-years OS for those transplanted after 2010 (87% vs. 63%, p = 0.01). Higher risk of death was associated with the use of haploidentical donor (HR8.86, p 0.021), unrelated cord blood (HR 8.76, p 0.005), unrelated donor (HR 5.91, p 0.02), and for HSCT performed before 2010 (HR 4.16, p = 0.0015). The CI of acute GVHD was 24.8%, while chronic GVHD was 9.5%. Major causes of death were infections (n = 8), GVHD (n = 6), and neurologic progression (n = 3). Despite improvements in transplant outcomes since 2011, challenges persist, emphasizing the need for early diagnosis, timely transplantation and expanding HSCT centers with expertise in the field.
- Open Access
- 13 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Chronic graft-versus-host-disease
Chronic GvHD is a major cause of non-relapse morbidity and mortality after hematopoietic cell transplantation. Its incidence has increased due to more frequent use of unrelated and/or mismatched donors, reduced intensity conditioning regimens or intensified regimens and PBSC grafts. The first-line therapy for chronic GvHD is systemic corticosteroids associated with either CNI or sirolimus, as a steroid sparing agent. Since children are more susceptible to the long-term steroid side effects, development of steroid-free strategies for front-line therapy is crucial. Sirolimus seems to be an interesting choice due to its capacity of inhibiting T-cells preserving the Tregs cells and antifibrotic, antineoplastic and antiviral activities. FAM regimen (Fluticasone, Azitromycin and Montelucaste) is recommended in combination with systemic steroids for initial treatment of bronchiolitis obliterans. For steroid-refractory chronic GvHD, ruxolitinib is the standard of care, while extracorporeal photopheresis can be combined for better results, however treatment costs are limitations. Extracorporeal photopheresis, treatment that preserves graft-versus-leukemia effect due to its steroid sparing and immunomodulatory actions, and mesenchymal stem cells, another non-pharmacological strategy that can be combined with the options mentioned above in severe chronic GvHD. Since access to novel drugs and extracorporeal photopheresis or mesenchymal stem cells is tough, other options approved for the third line and beyond are ibrutinib, belumosudil and axatilimab. Conventional agents could be used such as imatinib, low dose-MTX, rituximab, however the expected response rates are lower. We reviewed clinical studies and published recommendations on pediatric chronic GVHD that were presented in debate rounds with GvHD experts of the Pediatric group of the Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea (SBTMO). The goal of this consensus is to standardize the prophylaxis, diagnosis, grading and treatment of chronic GvHD among Brazilian pediatric HCT centers, to improve post-transplant outcomes.
- 13 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessChronic graft-versus-host-disease
Chronic GvHD is a major cause of non-relapse morbidity and mortality after hematopoietic cell transplantation. Its incidence has increased due to more frequent use of unrelated and/or mismatched donors, reduced intensity conditioning regimens or intensified regimens and PBSC grafts. The first-line therapy for chronic GvHD is systemic corticosteroids associated with either CNI or sirolimus, as a steroid sparing agent. Since children are more susceptible to the long-term steroid side effects, development of steroid-free strategies for front-line therapy is crucial. Sirolimus seems to be an interesting choice due to its capacity of inhibiting T-cells preserving the Tregs cells and antifibrotic, antineoplastic and antiviral activities. FAM regimen (Fluticasone, Azitromycin and Montelucaste) is recommended in combination with systemic steroids for initial treatment of bronchiolitis obliterans. For steroid-refractory chronic GvHD, ruxolitinib is the standard of care, while extracorporeal photopheresis can be combined for better results, however treatment costs are limitations. Extracorporeal photopheresis, treatment that preserves graft-versus-leukemia effect due to its steroid sparing and immunomodulatory actions, and mesenchymal stem cells, another non-pharmacological strategy that can be combined with the options mentioned above in severe chronic GvHD. Since access to novel drugs and extracorporeal photopheresis or mesenchymal stem cells is tough, other options approved for the third line and beyond are ibrutinib, belumosudil and axatilimab. Conventional agents could be used such as imatinib, low dose-MTX, rituximab, however the expected response rates are lower. We reviewed clinical studies and published recommendations on pediatric chronic GVHD that were presented in debate rounds with GvHD experts of the Pediatric group of the Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea (SBTMO). The goal of this consensus is to standardize the prophylaxis, diagnosis, grading and treatment of chronic GvHD among Brazilian pediatric HCT centers, to improve post-transplant outcomes.
- Open Access
- 7 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Acute graft-versus-host disease
Despite current advances in graft-versus-host disease (GvHD) prophylaxis, it remains one of the leading causes of morbidity and mortality after hematopoietic cell transplantation (HCT). The first-line therapy for acute GvHD is systemic corticosteroids, but about half of affected patients needs a second-line treatment. Ruxolitinib has been recommended for steroid-refractory GvHD, but treatment costs and adverse events such as cytopenias and infections are limitations. The main second-line alternatives for children are: basilixmab, an anti-interleukin-2-receptor monoclonal antibody, which showed good responses in skin and gut manifestations; extracorporeal photopheresis, treatment that preserves graft-versus-leukemia effect due to its steroid sparing and immunomodulatory actions, and mesenchymal stem cells, another non-pharmacological strategy that can be combined with the options mentioned before in severe acute GvHD. Novel therapeutical agents are emerging, but their efficacy and safety need further investigation in pediatric patients. We reviewed clinical studies and published recommendations on pediatric acute GvHD that were presented in debate rounds with GvHD experts of the Pediatric Group of the Brazilian Society for Cellular Therapy and Bone Marrow Transplantation. The goal of this consensus is to standardize the prophylaxis, diagnosis, grading, and treatment of acute GvHD among Brazilian pediatric HCT centers, to improve post-transplant outcomes.
- 7 January 2025
- Published by Journal of Bone Marrow Transplantation and Cellular Therapy in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Vol. 6 (1)
Open AccessAcute graft-versus-host disease
Despite current advances in graft-versus-host disease (GvHD) prophylaxis, it remains one of the leading causes of morbidity and mortality after hematopoietic cell transplantation (HCT). The first-line therapy for acute GvHD is systemic corticosteroids, but about half of affected patients needs a second-line treatment. Ruxolitinib has been recommended for steroid-refractory GvHD, but treatment costs and adverse events such as cytopenias and infections are limitations. The main second-line alternatives for children are: basilixmab, an anti-interleukin-2-receptor monoclonal antibody, which showed good responses in skin and gut manifestations; extracorporeal photopheresis, treatment that preserves graft-versus-leukemia effect due to its steroid sparing and immunomodulatory actions, and mesenchymal stem cells, another non-pharmacological strategy that can be combined with the options mentioned before in severe acute GvHD. Novel therapeutical agents are emerging, but their efficacy and safety need further investigation in pediatric patients. We reviewed clinical studies and published recommendations on pediatric acute GvHD that were presented in debate rounds with GvHD experts of the Pediatric Group of the Brazilian Society for Cellular Therapy and Bone Marrow Transplantation. The goal of this consensus is to standardize the prophylaxis, diagnosis, grading, and treatment of acute GvHD among Brazilian pediatric HCT centers, to improve post-transplant outcomes.
- 22 September 2021
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (2) , 715-723
Kidney complications in 107 Fanconi anemia patients submitted to hematopoietic cell transplantation
Fanconi anemia (FA) is a rare disease characterized by progressive bone marrow failure, cancer predisposition, and multiple systemic malformations, including congenital abnormalities of the kidney and urinary tract (CAKUT). Hematopoietic cell transplantation (HCT), the only potentially curative treatment for the hematological complications of FA, may precipitate acute kidney injury (AKI) and hypertension. We retrospectively investigated 107 FA patients who underwent HCT between 2009 and 2017. We investigated the incidence and risk factors of AKI within 100 days after HCT in a cohort of FA patients, and kidney function and hypertension over 2-year follow-up.The incidence of AKI (mainly stage I) was 18.7%. Patients aged ≥ 11 years at transplantation showed a higher risk of AKI (OR 3.53). The eGFR was 60–90 mL/min/1.73 m2 in 53 (49.5%), 55 (51.4%), 50 (50.5%), 50 (51%), and 46 (59.7%) patients before HCT, at 100 days, 6 months, 1 year, and 2 years. Within the first 100 days after HCT, hypertension was observed in 72% of the patients and was associated with cyclosporine therapy. Most (62.3%) patients had stage 2 hypertension. CAKUT was observed in 33.7% of the patients and was associated with both hypertension (86%) and diminished kidney function but not with AKI. Conlusion: Although AKI, a commonly known HCT complication, was mild in this study, the prevalence of chronic kidney disease (CKD), as well as the high incidence of hypertension, specially associated with CAKUT point out the importance of kidney care in short and long-term follow up of FA patients. What is Known: • Fanconi anemia (FA) is the most frequent inherited bone marrow failure in children, and 30% of cases have congenital anomalies of kidney (CAKUT). • Acute kidney injury and hypertension after hematopoietic cell transplantation (HCT) may impact the outcomes.. What is New: • Despite the presence of CAKUT and stage 2 CKD in 33.7% and 50% of the patients, respectively, AKI was mild and transitory after HCT in FA patients. • CAKUT in FA patients was associated with lower kidney function and hypertension after HCT.
- 22 September 2021
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (2) , 715-723
Kidney complications in 107 Fanconi anemia patients submitted to hematopoietic cell transplantation
Fanconi anemia (FA) is a rare disease characterized by progressive bone marrow failure, cancer predisposition, and multiple systemic malformations, including congenital abnormalities of the kidney and urinary tract (CAKUT). Hematopoietic cell transplantation (HCT), the only potentially curative treatment for the hematological complications of FA, may precipitate acute kidney injury (AKI) and hypertension. We retrospectively investigated 107 FA patients who underwent HCT between 2009 and 2017. We investigated the incidence and risk factors of AKI within 100 days after HCT in a cohort of FA patients, and kidney function and hypertension over 2-year follow-up.The incidence of AKI (mainly stage I) was 18.7%. Patients aged ≥ 11 years at transplantation showed a higher risk of AKI (OR 3.53). The eGFR was 60–90 mL/min/1.73 m2 in 53 (49.5%), 55 (51.4%), 50 (50.5%), 50 (51%), and 46 (59.7%) patients before HCT, at 100 days, 6 months, 1 year, and 2 years. Within the first 100 days after HCT, hypertension was observed in 72% of the patients and was associated with cyclosporine therapy. Most (62.3%) patients had stage 2 hypertension. CAKUT was observed in 33.7% of the patients and was associated with both hypertension (86%) and diminished kidney function but not with AKI. Conlusion: Although AKI, a commonly known HCT complication, was mild in this study, the prevalence of chronic kidney disease (CKD), as well as the high incidence of hypertension, specially associated with CAKUT point out the importance of kidney care in short and long-term follow up of FA patients. What is Known: • Fanconi anemia (FA) is the most frequent inherited bone marrow failure in children, and 30% of cases have congenital anomalies of kidney (CAKUT). • Acute kidney injury and hypertension after hematopoietic cell transplantation (HCT) may impact the outcomes.. What is New: • Despite the presence of CAKUT and stage 2 CKD in 33.7% and 50% of the patients, respectively, AKI was mild and transitory after HCT in FA patients. • CAKUT in FA patients was associated with lower kidney function and hypertension after HCT.
- Open Access
- 22 December 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (12) , e0169377
Correction: Factors Associated with Anemia in the Institutionalized Elderly
[This corrects the article DOI: 10.1371/journal.pone.0162240.].
- 22 December 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (12) , e0169377
Open AccessCorrection: Factors Associated with Anemia in the Institutionalized Elderly
[This corrects the article DOI: 10.1371/journal.pone.0162240.].